Literature DB >> 15720798

Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.

Jindrich Cinatl1, Martin Michaelis, Pablo Hernáiz Driever, Jaroslav Cinatl, Jan Hrabeta, Tatyana Suhan, Hans Wilhelm Doerr, Jens-Uwe Vogel.   

Abstract

The mode of the antitumoral activity of multimutated oncolytic herpes simplex virus type 1 G207 has not been fully elucidated yet. Because the antitumoral activity of many drugs involves the inhibition of tumor blood vessel formation, we determined if G207 had an influence on angiogenesis. Monolayers of human umbilical vein endothelial cells and human dermal microvascular endothelial cells, but not human dermal fibroblasts, bronchial epithelial cells, and retinal glial cells, were highly sensitive to the replicative and cytotoxic effects of G207. Moreover, G207 infection caused the destruction of endothelial cell tubes in vitro. In the in vivo Matrigel plug assay in mice, G207 suppressed the formation of perfused vessels. Intratumoral treatment of established human rhabdomyosarcoma xenografts with G207 led to the destruction of tumor vessels and tumor regression. Ultrastructural investigations revealed the presence of viral particles in both tumor and endothelial cells of G207-treated xenografts, but not in adjacent normal tissues. These findings show that G207 may suppress tumor growth, in part, due to inhibition of angiogenesis.

Entities:  

Mesh:

Year:  2004        PMID: 15720798      PMCID: PMC1531676          DOI: 10.1593/neo.04265

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  45 in total

Review 1.  Angiogenesis assays: a critical overview.

Authors:  Robert Auerbach; Rachel Lewis; Brenda Shinners; Louis Kubai; Nasim Akhtar
Journal:  Clin Chem       Date:  2003-01       Impact factor: 8.327

Review 2.  Clinical translation of angiogenesis inhibitors.

Authors:  Robert Kerbel; Judah Folkman
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

3.  Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus.

Authors:  H Petrowsky; G D Roberts; D A Kooby; B M Burt; J J Bennett; K A Delman; S F Stanziale; T M Delohery; W P Tong; H J Federoff; Y Fong
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.

Authors:  Jindrich Cinatl; Jaroslav Cinatl; Martin Michaelis; Hanka Kabickova; Rouslan Kotchetkov; Jens-Uwe Vogel; Hans Wilhelm Doerr; Thomas Klingebiel; Pablo Hernáiz Driever
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

5.  Human cytomegalovirus circumvents NF-kappa B dependence in retinal pigment epithelial cells.

Authors:  J Cinatl; S Margraf; J U Vogel; M Scholz; J Cinatl; H W Doerr
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

6.  Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

Authors:  F Farassati; A D Yang; P W Lee
Journal:  Nat Cell Biol       Date:  2001-08       Impact factor: 28.824

7.  The sponge/Matrigel angiogenesis assay.

Authors:  Nasim Akhtar; Erin B Dickerson; Robert Auerbach
Journal:  Angiogenesis       Date:  2002       Impact factor: 9.596

8.  Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses.

Authors:  Neeti S Bharatan; Mark A Currier; Timothy P Cripe
Journal:  J Pediatr Hematol Oncol       Date:  2002 Aug-Sep       Impact factor: 1.289

9.  Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.

Authors:  Stephen F Stanziale; Henrik Petrowsky; John K Joe; Gretchen D Roberts; Jonathan S Zager; Niraj J Gusani; Leah Ben-Porat; Mithat Gonen; Yuman Fong
Journal:  Surgery       Date:  2002-08       Impact factor: 3.982

Review 10.  Are tumours angiogenesis-dependent?

Authors:  H M W Verheul; E E Voest; R O Schlingemann
Journal:  J Pathol       Date:  2004-01       Impact factor: 7.996

View more
  20 in total

1.  ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

Authors:  J Carson; D Haddad; M Bressman; Y Fong
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

Review 2.  Impact of tumor microenvironment on oncolytic viral therapy.

Authors:  Jeffrey Wojton; Balveen Kaur
Journal:  Cytokine Growth Factor Rev       Date:  2010 Apr-Jun       Impact factor: 7.638

Review 3.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 4.  Advances in oncolytic virus therapy for glioma.

Authors:  Amy Haseley; Christopher Alvarez-Breckenridge; Abhik Ray Chaudhury; Balveen Kaur
Journal:  Recent Pat CNS Drug Discov       Date:  2009-01

5.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors:  Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

6.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Authors:  Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 7.  "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

Authors:  Balveen Kaur; Timothy P Cripe; E Antonio Chiocca
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

8.  Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.

Authors:  Kazuhiko Kurozumi; Jayson Hardcastle; Roopa Thakur; Joshua Shroll; Michal Nowicki; Akihiro Otsuki; E Antonio Chiocca; Balveen Kaur
Journal:  Mol Ther       Date:  2008-06-10       Impact factor: 11.454

Review 9.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15

10.  Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells.

Authors:  Martin Michaelis; Denise Klassert; Susanne Barth; Tatyana Suhan; Rainer Breitling; Bernd Mayer; Nora Hinsch; Hans W Doerr; Jaroslav Cinatl; Jindrich Cinatl
Journal:  Mol Cancer       Date:  2009-09-29       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.